Cargando…
Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled st...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485758/ https://www.ncbi.nlm.nih.gov/pubmed/37692262 http://dx.doi.org/10.5114/ada.2023.129456 |
_version_ | 1785102858095427584 |
---|---|
author | Bogacz-Piaseczyńska, Agnieszka Bożek, Andrzej Pastuszczak, Maciej Zalejska-Fiolka, Jolanta |
author_facet | Bogacz-Piaseczyńska, Agnieszka Bożek, Andrzej Pastuszczak, Maciej Zalejska-Fiolka, Jolanta |
author_sort | Bogacz-Piaseczyńska, Agnieszka |
collection | PubMed |
description | INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months’ AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed. RESULTS: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. CONCLUSIONS: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT. |
format | Online Article Text |
id | pubmed-10485758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-104857582023-09-09 Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites Bogacz-Piaseczyńska, Agnieszka Bożek, Andrzej Pastuszczak, Maciej Zalejska-Fiolka, Jolanta Postepy Dermatol Alergol Original Paper INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months’ AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed. RESULTS: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. CONCLUSIONS: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT. Termedia Publishing House 2023-07-14 2023-08 /pmc/articles/PMC10485758/ /pubmed/37692262 http://dx.doi.org/10.5114/ada.2023.129456 Text en Copyright: © 2023 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Bogacz-Piaseczyńska, Agnieszka Bożek, Andrzej Pastuszczak, Maciej Zalejska-Fiolka, Jolanta Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title | Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title_full | Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title_fullStr | Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title_full_unstemmed | Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title_short | Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
title_sort | molecular profiling of allergen-antibody ige might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485758/ https://www.ncbi.nlm.nih.gov/pubmed/37692262 http://dx.doi.org/10.5114/ada.2023.129456 |
work_keys_str_mv | AT bogaczpiaseczynskaagnieszka molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites AT bozekandrzej molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites AT pastuszczakmaciej molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites AT zalejskafiolkajolanta molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites |